Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4318 · 1 trial · 2 indications
Blood samples will be collected to determine the AUC0-inf of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the AUC0-24hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the C12hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the C24hrs of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Cmax of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Tmax of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the CL/F of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the Vz/F of MK-4318 in the presence of diltiazem.
Blood samples will be collected to determine the t1/2 of MK-4318 in the presence of diltiazem.
| Arm | Type | Description |
|---|---|---|
| MK-4318 Plus Diltiazem | EXPERIMENTAL | Participants will move sequentially through 2 Periods. In Period 1, participants receive MK-4318 orally. In Period 2, participants receive MK-4318 orally plus diltiazem orally. |
| Name | Type | Description |
|---|---|---|
| MK-4318 | DRUG | Oral administration |
| Diltiazem | DRUG | Oral administration |
Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Is in good health based on medical history and physical examination * Has a body mass index \>18 and ≤32 kg/m\^2, inclusive Exclusion Criteria The main exclusion criteria include but are not limited to...
MK-4318 is an investigational small molecule being developed by Merck & Company, Inc. for pain. It is currently in Phase 1 clinical development, studied in healthy volunteers to assess its safety and tolerability. It is not approved by the FDA and remains under clinical investigation.
MK-4318 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy participants.
MK-4318 is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 19 healthy participants in the United States. The drug is investigational and has not been approved by regulatory authorities.
MK-4318 has one completed clinical trial, NCT06692647, titled "A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)." This Phase 1 study enrolled 19 healthy adults in the United States and was not randomized, double-blind, or controlled.
No, MK-4318 is not the same as diltiazem. Diltiazem is a separate drug used in the clinical trial NCT06692647 to study potential interactions with MK-4318. MK-4318 is the investigational drug being evaluated for pain.